10-QPeriod: Q1 FY2024

ECOLAB INC. Quarterly Report for Q1 Ended Mar 31, 2024

Filed May 2, 2024For Securities:ECL

Summary

Ecolab Inc. reported a strong first quarter for 2024, with net sales increasing by 5% year-over-year to $3.75 billion, driven by a 5% increase in organic sales. The company demonstrated significant profit growth, with reported operating income up 47% to $517.9 million and net income attributable to Ecolab soaring 77% to $412.1 million. This robust performance was supported by an improved gross margin of 43.3% (up from 38.3% in the prior year) due to lower delivered product costs and effective pricing strategies. The company's strategic focus on efficiency and pricing power appears to be paying off, leading to substantial earnings per share growth. Ecolab also managed its debt effectively, reducing total debt by approximately $630 million in the quarter and maintaining a healthy net debt to EBITDA ratio of 2.2. Looking ahead, Ecolab has agreed to sell its global surgical solutions business for $950 million, which is expected to close in the second half of 2024 and generate a pre-tax gain, further strengthening its financial position and allowing for continued strategic investments.

Financial Highlights

54 data points
Beta

Revenue

$3.75B

43.3% Gross Margin

Net Income

$412.10M

11.0% Net Margin

EPS (Diluted)

$1.43

Total Assets

$21.30B

Cash & Equivalents

$479.90M

Free Cash Flow

$447.90M

Financial Statements
Beta
Revenue$3.75B
Cost of Revenue$2.13B
Gross Profit$1.62B
SG&A Expenses$1.08B
Operating Income$517.90M
Interest Expense$94.50M
Net Income$412.10M
EPS (Basic)$1.44
EPS (Diluted)$1.43
Shares Outstanding (Basic)285.70M
Shares Outstanding (Diluted)287.80M

Key Highlights

  • 1Net sales increased 5% to $3.75 billion, with organic sales also up 5%.
  • 2Reported operating income increased 47% to $517.9 million, and net income attributable to Ecolab grew 77% to $412.1 million.
  • 3Gross margin improved significantly to 43.3% from 38.3% in the prior year, driven by lower costs and strong pricing.
  • 4Diluted EPS increased 74% to $1.43, with adjusted diluted EPS up 52% to $1.34.
  • 5The company reduced its total debt by $630 million during the quarter, ending with $7.5 billion in total debt.
  • 6Cash provided by operating activities was strong at $649.4 million, a significant increase from $198.2 million in the prior year.
  • 7Ecolab announced the sale of its global surgical solutions business for $950 million, expected to close in the second half of 2024.

Frequently Asked Questions

Ecolab's revenue growth in Q1 2024 was driven by a 5% increase in net sales and a 5% increase in organic sales. This growth was fueled by strong performance across several segments, notably Global Institutional & Specialty with double-digit growth, and Global Pest Elimination showing 9% organic sales growth. Pricing actions and volume increases also contributed positively to the sales performance.

Profitability saw a significant improvement due to a 47% increase in reported operating income to $517.9 million and a 77% surge in net income attributable to Ecolab to $412.1 million. This was primarily driven by a substantial improvement in gross margin, which rose to 43.3% from 38.3% in the prior year, attributed to lower delivered product costs and effective pricing strategies. The company also benefited from a lower effective tax rate of 9.2% in Q1 2024 compared to 18.0% in Q1 2023, partly due to discrete tax benefits.

The planned sale of the global surgical solutions business for $950 million, expected to close in the second half of 2024, is a significant strategic move. It will generate substantial cash proceeds, which Ecolab expects to record as a pre-tax gain. This transaction will likely strengthen the company's financial position, allowing for continued strategic investments and potentially further capital allocation to shareholders, while allowing Ecolab to focus on its core businesses.

Ecolab is actively managing its debt, reducing total debt by $630 million in Q1 2024, ending the quarter with $7.5 billion in total debt. The company maintained a healthy net debt to EBITDA ratio of 2.2. Ecolab also generated strong operating cash flow of $649.4 million, indicating robust liquidity. The company has a $2.0 billion revolving credit facility and no outstanding commercial paper, suggesting a solid liquidity position to fund operations, investments, and shareholder returns.